Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Inclusion Criteria:

• Patients with a first diagnosis of HCC who have undergone a curative resection
• Radiologic evidence of disease free ≥4 weeks after complete surgical resection
• Full recovery from surgical resection or post-operative transarterialchemoembolization before randomization
• Randomization needs to occur within 12 weeks of the date of surgical resection
• High risk for HCC recurrence as protocol defined
• Child-Pugh Score, Class A
• ECOG performance status 0 or 1
• No prior systemic anticancer therapy for HCC
• Adequate hematologic and organ function

Exclusion Criteria:

• Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
• Evidence of residual, recurrent, or metastatic disease at randomization
• History of hepatic encephalopathy or organ transplantation
• Patients who are in the waiting list for liver transplantation
• Patients with Vp4 portal vein thrombosis
• Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or otherimmunotherapy
• Pregnant or lactating women